MicroRNA-210 as a prognostic factor in patients with breast cancer: Meta-analysis

Cancer Biomarkers

Volumn 13, Issue 6, 2013, Pages 471-481

  Li, Yanyan ^a   Ma, Xuelei ^a   Zhao, Jingyi ^a   Zhang, Binglan ^a   Jing, Zhang ^a   Liu, Lei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

breast cancer; meta analysis; microRNA 210; prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; META ANALYSIS; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 84896078414     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130385     Document Type: Article

References (32)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, CA Cancer J Clin 61 (2011), 69-90.
2. O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, N. Harbeck, Triple-negative breast cancer - current status and future directions, Ann Oncol 20 (2009), 1913-1927.
3. H. Yamashiro, M. Toi, Update of evidence in chemotherapy for breast cancer, Int J Clin Oncol 13 (2008), 3-7.
4. M.S. Nicoloso, R. Spizzo, M. Shimizu, S. Rossi, G.A. Calin, MicroRNAs - the micro steering wheel of tumour metastases, Nat Rev Cancer 9 (2009), 293-302.
5. D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004), 281-297.
6. C. Caldas, J.D. Brenton, Sizing up miRNAs as cancer genes, Nat Med 11 (2005), 712-714.
7. A. Osman, MicroRNAs in health and disease - basic science and clinical applications, Clin Lab 58 (2012), 393-402.
8. Y.W. Kong, D. Ferland-McCollough, T.J. Jackson, M. Bushell, microRNAs in cancer management, Lancet Oncol 13 (2012), e249-258.
9. M. Redova, A. Poprach, A. Besse, R. Iliev, J. Nekvindova, R. Lakomy, L. Radova, M. Svoboda, J. Dolezel, R. Vyzula, O. Slaby, MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma, Tumour Biol 34 (2013), 481-491.
10. L. Hong, J. Yang, Y. Han, Q. Lu, J. Cao, L. Syed, High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis, Gene 507 (2012), 135-138.
11. M.K. Parmar, V. Torri, L. Stewart, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med 17 (1998), 2815-2834.
12. P.R. Williamson, C.T. Smith, J.L. Hutton, A.G. Marson, Aggregate data meta-analysis with time-to-event outcomes, Stat Med 21 (2002), 3337-3351.
13. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, M.R. Sydes, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials 8 (2007), 16.
14. C.B. Begg, A comparison of methods to detect publication bias in meta-analysis by P. Macaskill, S. D. Walter and L. Irwig, Stat Med 21 (2002), 1803.
15. S. Volinia, M. Galasso, M.E. Sana, T.F. Wise, J. Palatini, K. Huebner, C.M. Croce, Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA, Proc Natl Acad Sci U S A 109 (2012), 3024-3029.
16. T. Toyama, N. Kondo, Y. Endo, H. Sugiura, N. Yoshimoto, M. Iwasa, S. Takahashi, Y. Fujii, H. Yamashita, High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients, Jpn J Clin Oncol 42 (2012), 256-263.
17. F. Rothe, M. Ignatiadis, C. Chaboteaux, B. Haibe-Kains, N. Kheddoumi, S. Majjaj, B. Badran, H. Fayyad-Kazan, C. Desmedt, A.L. Harris, M. Piccart, C. Sotiriou, Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer, PLoS One 6 (2011), e20980.
18. J. Radojicic, A. Zaravinos, T. Vrekoussis, M. Kafousi, D.A. Spandidos, E.N. Stathopoulos, MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer, Cell Cycle 10 (2011), 507-517.
19. F.M. Buffa, C. Camps, L. Winchester, C.E. Snell, H.E. Gee, H. Sheldon, M. Taylor, A.L. Harris, J. Ragoussis, microRNAassociated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer, Cancer Res 71 (2011), 5635- 5645.
20. J.A. Foekens, A.M. Sieuwerts, M. Smid, M.P. Look, V. de Weerd, A.W. Boersma, J.G. Klijn, E.A. Wiemer, J.W. Martens, Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer, Proc Natl Acad Sci U S A 105 (2008), 13021- 13026.
21. C. Camps, F.M. Buffa, S. Colella, J. Moore, C. Sotiriou, H. Sheldon, A.L. Harris, J.M. Gleadle, J. Ragoussis, hsa-miR- 210 Is induced by hypoxia and is an independent prognostic factor in breast cancer, Clin Cancer Res 14 (2008), 1340- 1348.
22. J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B.L. Ebert, R.H. Mak, A.A. Ferrando, J.R. Downing, T. Jacks, H.R. Horvitz, T.R. Golub, MicroRNA expression profiles classify human cancers, Nature 435 (2005), 834-838.
23. V.N. Kim, J. Han, M.C. Siomi, Biogenesis of small RNAs in animals, Nat Rev Mol Cell Biol 10 (2009), 126-139.
24. R. Kulshreshtha, M. Ferracin, S.E. Wojcik, R. Garzon, H. Alder, F.J. Agosto-Perez, R. Davuluri, C.G. Liu, C.M. Croce, M. Negrini, G.A. Calin, M. Ivan, A microRNA signature of hypoxia, Mol Cell Biol 27 (2007), 1859-1867.
25. E. Duncavage, B. Goodgame, A. Sezhiyan, R. Govindan, J. Pfeifer, Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer, J Thorac Oncol 5 (2010), 1755-1763.
26. H.E. Gee, F.M. Buffa, C. Camps, A. Ramachandran, R. Leek, M. Taylor, M. Patil, H. Sheldon, G. Betts, J. Homer, C. West, J. Ragoussis, A.L. Harris, The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis, Br J Cancer 104 (2011), 1168- 1177.
27. U. Vosa, T. Vooder, R. Kolde, J. Vilo, A. Metspalu, T. Annilo, Meta-analysis of microRNA expression in lung cancer, Int J Cancer (2012).
28. C.S. Neal, M.Z.Michael, L.H. Rawlings, M.B. Van der Hoek, J.M. Gleadle, The VHL-dependent regulation of microRNAs in renal cancer, BMC Med 8 (2010), 64.
29. T. Greither, L.F. Grochola, A. Udelnow, C. Lautenschlager, P. Wurl, H. Taubert, Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival, Int J Cancer 126 (2010), 73-80.
30. G.L. Semenza, P.H. Roth, H.M. Fang, G.L. Wang, Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1, J Biol Chem 269 (1994), 23757- 23763.
31. R.H. Wenger, M. Gassmann, Oxygen(es) and the hypoxiainducible factor-1, Biol Chem 378 (1997), 609-616.
32. M. Egger, T. Zellweger-Zahner, M. Schneider, C. Junker, C. Lengeler, G. Antes, Language bias in randomised controlled trials published in English and German, Lancet 350 (1997), 326-329.